| Budget Amount *help |
¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2016: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2015: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2014: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
|---|
| Outline of Final Research Achievements |
The clearance of amyloid β from the brain could be a novel therapeutic target for Alzheimer’s disease (AD). Although LRP1 and ABC transporters were the Aβ transporters at the blood-brain barrier (BBB), conflicting data exist regarding the contribution of these proteins to the clearance of Aß through the BBB. In this study, we examined the expression of LRP1, p-glycoprotein, ABCG2 in the human brain pericytes (HBPCT) and human brain microvascular endothelial cells (HBMECs) using real time PCR, western blot, and immunostaining analyses. LRP1 were mainly expressed in HBPCT, not HBMECs. On the other hand, P-glycoprotein and ABCG2 were predominantly expressed in HBMECs. In addition, we disclosed that RAP, an inhibitor of LRP1, deceased the uptake of FAM-Aβ40 into HBPCT cells. These results indicated that Aβ could be transported across not only HBMEC but also HBPCTs via these receptor and transporter.
|
